TY - JOUR
T1 - In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas
T2 - feasibility and accuracy in a clinical setting
AU - Cuccarini, Valeria
AU - Antelmi, Luigi
AU - Pollo, Bianca
AU - Paterra, Rosina
AU - Calatozzolo, Chiara
AU - Nigri, Anna
AU - DiMeco, Francesco
AU - Eoli, Marica
AU - Finocchiaro, Gaetano
AU - Brenna, Greta
AU - Tramacere, Irene
AU - Bruzzone, Maria Grazia
AU - Anghileri, Elena
N1 - Funding Information:
We thank Federico Riccardi Sirtori (Oncology Unit, Nerviano Medical Sciences, Nerviano (MI)) for dosing 2HG in biological fluids and Ruben Gianeri (Unit of Neuroradiology, FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA) for the help with MR imaging. We absolutely thank our patients.
Publisher Copyright:
© 2019, Fondazione Società Italiana di Neurologia.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Abstract: Isocitrate dehydrogenase 1/2 (IDH1/2) mutations are often detected in lower-grade gliomas (LGG) and result into 2-hydroxyglutarate (2HG) synthesis. Prior studies showed that 2HG can be detected in vivo using magnetic resonance spectroscopy (MRS), but its accuracy and translational impact are still under investigation. Purpose: To investigate the clinical feasibility of MRS for in vivo detection and quantification of 2HG on consecutive treatment-naïve suspect LGG patients and to compare MRS accuracy with tissue IDH1/2 analysis. Methods: MRS spectra at 3 T were acquired with 1H-MRS single-voxel PRESS 2HG-tailored sequences with TE 30 (group 1) or TE 97 (groups 2A and B). Voxel sizes were 1.5 × 1.5 × 1.5 cm3 for group 1 (n = 13) and group 2A (n = 14) and 2 × 2 × 2 cm3 for group 2B (n = 32). Multiple metabolites’ concentrations were analyzed with LCModel. Tumors were assessed for IDH status and main molecular markers. 2HG levels in urine/blood were measured by liquid chromatography–mass spectrometry. Results: The larger voxel TE 97 sequence resulted in highest specificity (100%), sensitivity (79%), and accuracy (87%). Urine and blood 2HG did not result predictive. Conclusion: Our data confirm that 2 × 2 × 2-cm3 voxel TE 97 MRS shows high accuracy for 2HG detection, with good sensitivity and 100% specificity in distinguishing IDH mutant gliomas. Main limits of the technique are small tumor volume and low cellularity. Integrating 2HG-MRS with other metabolites may help non-invasive diagnosis of glioma, prognostic assessment, and treatment planning in clinical setting.
AB - Abstract: Isocitrate dehydrogenase 1/2 (IDH1/2) mutations are often detected in lower-grade gliomas (LGG) and result into 2-hydroxyglutarate (2HG) synthesis. Prior studies showed that 2HG can be detected in vivo using magnetic resonance spectroscopy (MRS), but its accuracy and translational impact are still under investigation. Purpose: To investigate the clinical feasibility of MRS for in vivo detection and quantification of 2HG on consecutive treatment-naïve suspect LGG patients and to compare MRS accuracy with tissue IDH1/2 analysis. Methods: MRS spectra at 3 T were acquired with 1H-MRS single-voxel PRESS 2HG-tailored sequences with TE 30 (group 1) or TE 97 (groups 2A and B). Voxel sizes were 1.5 × 1.5 × 1.5 cm3 for group 1 (n = 13) and group 2A (n = 14) and 2 × 2 × 2 cm3 for group 2B (n = 32). Multiple metabolites’ concentrations were analyzed with LCModel. Tumors were assessed for IDH status and main molecular markers. 2HG levels in urine/blood were measured by liquid chromatography–mass spectrometry. Results: The larger voxel TE 97 sequence resulted in highest specificity (100%), sensitivity (79%), and accuracy (87%). Urine and blood 2HG did not result predictive. Conclusion: Our data confirm that 2 × 2 × 2-cm3 voxel TE 97 MRS shows high accuracy for 2HG detection, with good sensitivity and 100% specificity in distinguishing IDH mutant gliomas. Main limits of the technique are small tumor volume and low cellularity. Integrating 2HG-MRS with other metabolites may help non-invasive diagnosis of glioma, prognostic assessment, and treatment planning in clinical setting.
KW - 2-hydroxyglutarate (2HG)
KW - Glioma
KW - Isocitrate dehydrogenase (IDH)
KW - Magnetic resonance spectroscopy (MRS)
KW - Point-resolved spectroscopy (PRESS)
UR - http://www.scopus.com/inward/record.url?scp=85074321629&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074321629&partnerID=8YFLogxK
U2 - 10.1007/s10072-019-04087-9
DO - 10.1007/s10072-019-04087-9
M3 - Article
C2 - 31650436
AN - SCOPUS:85074321629
VL - 41
SP - 347
EP - 355
JO - Neurological Sciences
JF - Neurological Sciences
SN - 1590-1874
IS - 2
ER -